ACE2 and COVID-19: Studies have also shown that ACE2 overexpression occurs in the nasal and oropharyngeal epithelium of individuals who are more vulnerable to severe COVID-19 symptoms (Chua et al., 2020; Li et al., 2020a; Ziegler et al., 2020).